Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Core Laboratories Inc has a consensus price target of $16 based on the ratings of 5 analysts. The high is $20 issued by Morgan Stanley on September 26, 2022. The low is $13 issued by Citigroup on May 13, 2025. The 3 most-recent analyst ratings were released by Citigroup, Stifel, and Citigroup on May 13, 2025, April 15, 2025, and March 12, 2025, respectively. With an average price target of $14.67 between Citigroup, Stifel, and Citigroup, there's an implied 18.18% upside for Core Laboratories Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/13/2025 | Buy Now | 4.75% | Citigroup | Scott Gruber62% | $16 → $13 | Maintains | Neutral | Get Alert |
04/15/2025 | Buy Now | 20.87% | Stifel | Stephen Gengaro55% | $19 → $15 | Maintains | Hold | Get Alert |
03/12/2025 | Buy Now | 28.93% | Citigroup | Scott Gruber62% | $15 → $16 | Upgrade | Sell → Neutral | Get Alert |
02/20/2025 | Buy Now | 20.87% | Citigroup | Scott Gruber62% | $14 → $15 | Maintains | Sell | Get Alert |
10/31/2024 | Buy Now | 12.81% | Citigroup | Scott Gruber62% | $15 → $14 | Maintains | Sell | Get Alert |
07/26/2024 | Buy Now | 77.28% | Stifel | Stephen Gengaro55% | $18 → $22 | Maintains | Hold | Get Alert |
07/15/2024 | Buy Now | 20.87% | B of A Securities | Chase Mulvehill48% | $16 → $15 | Maintains | Underperform | Get Alert |
07/15/2024 | Buy Now | 36.99% | Piper Sandler | Luke Lemoine50% | $18 → $17 | Maintains | Neutral | Get Alert |
04/26/2024 | Buy Now | 45.04% | Stifel | Stephen Gengaro55% | $17 → $18 | Maintains | Hold | Get Alert |
04/15/2024 | Buy Now | 28.93% | B of A Securities | Chase Mulvehill48% | $17 → $16 | Maintains | Underperform | Get Alert |
02/05/2024 | Buy Now | 36.99% | Stifel | Stephen Gengaro55% | $21 → $17 | Maintains | Hold | Get Alert |
01/29/2024 | Buy Now | 69.22% | Stifel | Stephen Gengaro55% | $23 → $21 | Maintains | Hold | Get Alert |
09/18/2023 | Buy Now | 61.16% | Citigroup | Scott Gruber62% | $21 → $20 | Maintains | Sell | Get Alert |
07/31/2023 | Buy Now | 69.22% | Piper Sandler | Luke Lemoine50% | $19 → $21 | Maintains | Neutral | Get Alert |
06/30/2023 | Buy Now | 69.22% | Citigroup | Scott Gruber62% | $22 → $21 | Downgrade | Neutral → Sell | Get Alert |
05/01/2023 | Buy Now | 53.1% | Piper Sandler | Luke Lemoine50% | $18 → $19 | Maintains | Neutral | Get Alert |
04/28/2023 | Buy Now | 101.45% | Stifel | Stephen Gengaro55% | $24 → $25 | Maintains | Hold | Get Alert |
04/18/2023 | Buy Now | 73.25% | B of A Securities | Chase Mulvehill48% | → $21.5 | Downgrade | Neutral → Underperform | Get Alert |
02/07/2023 | Buy Now | 109.51% | Citigroup | Scott Gruber62% | $21 → $26 | Maintains | Neutral | Get Alert |
01/09/2023 | Buy Now | — | B of A Securities | Chase Mulvehill48% | — | Upgrade | Underperform → Neutral | Get Alert |
10/07/2022 | Buy Now | — | Citigroup | Scott Gruber62% | — | Upgrade | Sell → Neutral | Get Alert |
09/26/2022 | Buy Now | 61.16% | Morgan Stanley | Connor Lynagh58% | → $20 | Downgrade | Equal-Weight → Underweight | Get Alert |
08/01/2022 | Buy Now | 61.16% | Morgan Stanley | Connor Lynagh58% | $22 → $20 | Maintains | Equal-Weight | Get Alert |
07/13/2022 | Buy Now | 77.28% | Morgan Stanley | Connor Lynagh58% | $32 → $22 | Maintains | Equal-Weight | Get Alert |
The latest price target for Core Laboratories (NYSE:CLB) was reported by Citigroup on May 13, 2025. The analyst firm set a price target for $13.00 expecting CLB to rise to within 12 months (a possible 4.75% upside). 8 analyst firms have reported ratings in the last year.
The latest analyst rating for Core Laboratories (NYSE:CLB) was provided by Citigroup, and Core Laboratories maintained their neutral rating.
The last upgrade for Core Laboratories Inc happened on March 12, 2025 when Citigroup raised their price target to $16. Citigroup previously had a sell for Core Laboratories Inc.
The last downgrade for Core Laboratories Inc happened on June 30, 2023 when Citigroup changed their price target from $22 to $21 for Core Laboratories Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Core Laboratories, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Core Laboratories was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
While ratings are subjective and will change, the latest Core Laboratories (CLB) rating was a maintained with a price target of $16.00 to $13.00. The current price Core Laboratories (CLB) is trading at is $12.41, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.